AXIM AXIM Biotechnologies Inc.

AXIM Biotechnologies, Inc. is a biotechnology company. It focuses in the research, development, and production of pharmaceutical, nutraceutical, cosmetic, and genetically controlled botanical products. The firm also involves in the extraction and purification of cannabinoids technologies based on its proprietary technologies. Its products include CBD-based controlled release chewing gum under CanChew brand; and a combination of CBD and THC gum that treats pain and spasticity associated with multiple sclerosis under MedChew Rx brand. The company was founded on November 18, 2010 and is headquartered in New York, NY.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.23    OTCQB
As of 01/24/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  10/09/2013
Outstanding shares:  138,599,981
Average volume:  238,336
Market cap:   $32,903,635
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -3.17
PB ratio:   6.98
PS ratio:   -541.28
Return on equity:   -223.33%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy